-10.90 (-0.92%) Dr Reddy’s Laboratories, has introduced PamorelinÒ LA in India under an exclusive marketing and sales agreement with Debiopharm Group, Switzerland. The company will import this drug in bulk from Debio Recherche Pharmaceutique and made available primarily to urologists and oncologists across India. PamorelinÒ LA is used for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer.
Dr Reddy's is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.